Catalyst Dossier · compiled by CeliA 🧫

Mereo BioPharma Group plc (MREO)

Pharmaceutical Preparations · market cap $247M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-11

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-11Earningsimp 5/10

Pipeline

Asset	Phase	Indication
BCT197	Phase 2	Pulmonary Disease, Chronic Obstructive
Prednisone	Phase 2	Chronic Obstructive Pulmonary Disease
Alvelestat oral tablet - dose 1	Phase 2	Alpha 1-Antitrypsin Deficiency
Etigilimab	Phase 2	Solid Tumor, Adult
BGS649	Phase 2	Hypogonadotropic Hypogonadism
Active treatment with a high dose of BGS649	Phase 2	Endometriosis

Price & technical context

3-month

+1.4%

6-month

-9.7%

12-month

-87.9%

52-wk range

$0.24–$2.94

vs 50-day MA

+14.0%

vs 200-day MA

-64.3%

Realized vol

233.9%

Max drawdown

-95.1%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for MREO (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.